Austin, Texas; March 14, 2012 Akela Pharma, Inc. (TSX:AKL) today announced that Gregory McKee, for

MassBioEd Contact Search Member Portal Create Member Portal Account Home About Mission & Values MassBio Board of Directors advanced consulting group About MassBioEd MassBio Staff Contact Us Directions Membership Membership FAQ Membership Directory The Forums Professional Development Join MassBio Apply Online! Purchasing See the Savings advanced consulting group MassBio Purchasing Consortium Suppliers Additional Savings Employee Perks Program Events Calendar Sponsorship Post Event Signature Events Locate & Grow The Massachusetts Supercluster Incentives Real Estate Biopharma Manufacturing in MA The MA CRO CMO Cluster Initiative Incubators in MA BioReady Communities Policy State Issues Federal Issues advanced consulting group MassBio PAC Innovation Services Pharma Days MassCONNECT Innovation advanced consulting group Exchange Therapeutic Opportunities Index Funding advanced consulting group Opportunities advanced consulting group Innovation Resources News MassBio Member News MassBio In The Media PRNewswire GlobeNewswire For Journalists Newsletter Archives RSS Feeds Careers Search Jobs or Internships advanced consulting group Post a Job or Internship Careers Page FAQs Member Portal My Profile advanced consulting group My Company My Membership Membership Events Career Listings The Forums Past Presentations & Video Video Resources Employee Perks Program MassBio HRonline Knowledge Base
Austin, Texas; March 14, 2012 Akela Pharma, Inc. (TSX:AKL) today announced that Gregory McKee, formerly advanced consulting group President and CEO, is no longer with the company. Rudy Emmelot, Akela s chief financial officer and a 6 year company veteran advanced consulting group has been appointed as acting president and chief executive officer.
Mr. Emmelot joined advanced consulting group Akela Pharma, Inc. in September advanced consulting group 2005 and has served as Akela s CFO since 2009. Mr. Emmelot has over two decades of experience in the biotech and healthcare industries. advanced consulting group Prior to joining Akela, Mr. Emmelot served as a senior executive at several companies most recently as vice president of Finance for Xencor, Inc.
Greg s efforts in moving the company forward in a challenging business environment have been important to Akela, and we thank him for his dedicated effort in that regard said Mr. Robert Rieder, Chairman of the Board of Akela. We will continue to dedicate our efforts toward increasing the sales and profitability of Akela s principle advanced consulting group asset, advanced consulting group our PharmaForm subsidiary.
About advanced consulting group Akela Pharma, Inc. Akela Pharma, Inc. is the parent company of PharmaForm, and its common shares trade on The Toronto Stock Exchange ( TSX ) under the symbol AKL with 32.4 million shares outstanding.
About advanced consulting group PharmaForm PharmaForm, a wholly-owned subsidiary of Akela Pharma, Inc., is a leading specialty advanced consulting group contract manufacturer in the area of pharmaceutical dosage form development, specializing in controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying, fluid bed processing, and liquid filled capsules. Through its diverse offerings, PharmaForm solutions help pharmaceutical and biotechnology advanced consulting group clients reach their drug development targets, reduce development costs and accelerate time-to-market for their products.
This advanced consulting group press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United advanced consulting group States Private Securities Litigation Reform Act of 1955. Such forward-looking statements or information may include financial and other projections as well as statements regarding the company s future plans, objectives, performance, advanced consulting group revenues, growth, profits, operating expenses or the company s underlying assumptions. The words may , would , could , will , likely , expect , anticipate , intend , plan , forecast , project , estimate and believe or other similar words and phrases advanced consulting group may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only expectations, and that the company s actual future results or performance may be materially different.
Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning our ongoing drug development programs and collaborations as well as the possible receipt of future payments upon achievement of milestones.
Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned advanced consulting group in a manner that would impair our ability to advance development; risks associated with the requirement that a drug candi